New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
10:02 EDTWFM, MIICF, MDT, ENB, STM, MPO, JNJ, OSK, MSFT, HTWR, BEP, OFC, CIB, GLW, ANFGYOn The Fly: Analyst Downgrade Summary
Antofagasta (ANFGY) downgraded to Hold from Buy at Canaccord... Bancolombia (CIB) downgraded to Neutral from Overweight at JPMorgan... Brookfield Renewable (BEP) downgraded to Neutral from Outperform at Credit Suisse... Corning (GLW) downgraded to Hold from Buy at Stifel... Corporate Office Properties (OFC) downgraded to Neutral from Buy at ISI Group... Enbridge (ENB) downgraded to Neutral from Outperform at Credit Suisse... HeartWare (HTWR) downgraded to Sell from Neutral at Goldman... Johnson & Johnson (JNJ) downgraded to Hold from Buy at Jefferies... Medtronic (MDT) downgraded to Neutral from Overweight at JPMorgan... Microsoft (MSFT) downgraded to Hold from Buy at Deutsche Bank... Midstates Petroleum (MPO) downgraded to Hold from Buy at MLV & Co... Millicom (MIICF) downgraded to Sell from Hold at Berenberg... Oshkosh (OSK) downgraded to Accumulate from Buy at Global Hunter... STMicroelectronics (STM) downgraded to Sell from Neutral at UBS... Whole Foods (WFM) downgraded to Hold from Buy at BB&T...
News For ANFGY;CIB;BEP;GLW;OFC;ENB;HTWR;JNJ;MDT;MSFT;MPO;MIICF;OSK;STM;WFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 11, 2014
08:53 EDTMSFTBritain lays out details for proposed 25% 'Google Tax,' WSJ reports
U.S. technology giants such as Google (GOOGL, GOOG), Facebook (FB), Microsoft (MSFT) and Apple (AAPL) have come under fire in Britain for the relatively small corporate taxes they pay there and the U.K. government detailed plans for a new 25% tax on profits of multinational technology and other companies, reported The Wall Street Journal. Reference Link
08:09 EDTMSFTGoogle shares pricing in loss of Apple search deal, says Citigroup
Subscribe for More Information
December 10, 2014
11:50 EDTSTMSTMicroelectronics downgraded to Neutral from Buy at UBS
Subscribe for More Information
09:22 EDTMSFTMicrosoft management to meet with Pacific Crest
Meeting to be held on the West Coast on December 12 hosted by Pacific Crest.
09:20 EDTMSFTTyler Technologies signs agreement with Albermarle County Service Authority
Tyler Technologies (TYL) has signed an agreement with the Albemarle County Service Authority to implement Microsoft Dynamics AX, an enterprise resource planning solution with public sector functionality that Tyler Technologies jointly developed with Microsoft (MSFT). The contract includes implementation and related professional services, support, and training.
08:46 EDTSTMSTMicroelectronics, others develop accurate analyzer for Ebola detection
Subscribe for More Information
06:04 EDTOFCCorporate Office Properties to deliver new build-to-suit project in Ashburn, VA
Subscribe for More Information
December 9, 2014
08:35 EDTGLWCorning Gorilla Glass 4 chosen for Samsung Galaxy ALPHA
Subscribe for More Information
06:27 EDTMSFTSamsung, white-box makers to benefit from Microsoft Mobile exit, DigiTimes says
Subscribe for More Information
06:09 EDTWFMStocks with implied volatility below IV index mean; PCLN WFM
Stocks with implied volatility below IV index mean; Priceline (PCLN) 20, Whole Foods (WFM) 20 according to iVolatility.
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
16:19 EDTMPOMidstates Petroleum announces termination of DeQuincy assets sales agreement
Subscribe for More Information
13:21 EDTMSFTMicrosoft files appeal in case on customer data in Ireland
Microsoft said on its blog that it has filed an appeal in its ongoing case challenging a U.S. government search warrant for customer data stored in Ireland. Microsoft said it filed the appeal after a U.S. district court judge rejected the company’s argument that the warrant is illegal because it calls for the seizure of emails stored outside the United States. Reference Link
12:40 EDTMSFTOn The Fly: Midday Wrap
Subscribe for More Information
10:44 EDTMSFTDigital River grants Microsoft extestion to decide on renewing pact
Subscribe for More Information
10:04 EDTMSFTAccenture and Microsoft launch hybrid cloud platform
Subscribe for More Information
06:13 EDTWFMStocks with implied volatility below IV index mean; WFM V
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use